This study, PTT101 (ClinicalTrials.Gov ID: NCT06132737), is a prospective, open-label dose-escalation, multicenter study to evaluate the safety, tolerability, biodistribution and efficacy of PentixaTher in patients with CNS lymphoma (cancer affecting the central nervous systems). PentixaTher is targeting the CXCR-4 cytokine receptor which is widely expressed in different cancer indications.
Before treatment, patients will be screened with Gallium-68 (68Ga)-based PentixaFor to confirm the presence of the CXCR-4 receptors. If the PET scan turns out to be positive, PentixaTher will be given in various doses to different dose group (in total 9 to 15 patients). The enrollment is planned to last 12 months.
“Previous studies have shown that up to 90% of CNS lymphoma patients overexpress the CXCR4 receptor. We therefore hope that the clinical results in CNS lymphomas with Yttrium (90Y) anditixafortide PentixaTher will show similar outstanding effects on tumor growth as we have observed it in other indications like T-cell lymphomas or Multiple Myelomas” commented Dr. Hakim Bouterfa, Chief Medical Officer at Eckert & Ziegler, and Member of the Board at Pentixapharm AG.
Eckert & Ziegler Strahlen- und Medizintechnik AG with more than 1.000 employees is a leading specialist for isotope-related components in nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the SDAX index of Deutsche Börse.
Contributing to saving lives.
Eckert & Ziegler Strahlen- und Medizintechnik AG
Robert-Rössle-Str. 10
13125 Berlin
Telefon: +49 (30) 941084-0
Telefax: +49 (30) 941084-112
http://www.ezag.de
Investor Relations
Telefon: +49 (30) 941084-138
Fax: +49 (30) 941084-112
E-Mail: karolin.riehle@ezag.de
